Related references
Note: Only part of the references are listed.Mapping and Characterization of Vicriviroc Resistance Mutations From HIV-1 Isolated from Treatment-Experienced Subjects Enrolled in a Phase II Study (VICTOR-E1)
Paul M. McNicholas et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2011)
New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection
Javier Garcia-Perez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc
Pierre Delobel et al.
AIDS (2010)
HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry
John C. Tilton et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate
Timothy J. Henrich et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Characterization of Emergent HIV Resistance in Treatment-Naive Subjects Enrolled in a Vicriviroc Phase 2 Trial
Paul McNicholas et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates
Nina H. Lin et al.
JOURNAL OF VIROLOGICAL METHODS (2010)
Rapid Dissociation of HIV-1 from Cultured Cells Severely Limits Infectivity Assays, Causes the Inactivation Ascribed to Entry Inhibitors, and Masks the Inherently High Level of Infectivity of Virions
Emily J. Platt et al.
JOURNAL OF VIROLOGY (2010)
HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4+ T Cells
Jennifer M. Pfaff et al.
JOURNAL OF VIROLOGY (2010)
Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5
Robert A. Ogert et al.
VIROLOGY (2010)
Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing
John Archer et al.
AIDS (2009)
HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes
Kosuke Miyauchi et al.
CELL (2009)
HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide
Neelanjana Ray et al.
JOURNAL OF VIROLOGY (2009)
A Quantitative Affinity-Profiling System That Reveals Distinct CD4/CCR5 Usage Patterns among Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Strains
Samantha H. Johnston et al.
JOURNAL OF VIROLOGY (2009)
Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo
Athe M. N. Tsibris et al.
PLOS ONE (2009)
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41
Cleo G. Anastassopoulou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities
Pavel Pugach et al.
VIROLOGY (2009)
Elite Suppressor-Derived HIV-1 Envelope Glycoproteins Exhibit Reduced Entry Efficiency and Kinetics
Kara G. Lassen et al.
PLOS PATHOGENS (2009)
Early Steps of HIV-1 Fusion Define the Sensitivity to Inhibitory Peptides That Block 6-Helix Bundle Formation
Kosuke Miyauchi et al.
PLOS PATHOGENS (2009)
Variable Fitness Impact of HIV-1 Escape Mutations to Cytotoxic T Lymphocyte (CTL) Response
Ryan M. Troyer et al.
PLOS PATHOGENS (2009)
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject
Athe M. N. Tsibris et al.
JOURNAL OF VIROLOGY (2008)
Molecular architecture of native HIV-1 gp120 trimers
Jun Liu et al.
NATURE (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1
Alonso Heredia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120
Robert A. Ogert et al.
VIROLOGY (2008)
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment experienced patients: AIDS clinical trials group 5211
Roy M. Gulick et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
High throughput functional analysis of HIV-1 env genes without cloning
Jennifer L. Kirchherr et al.
JOURNAL OF VIROLOGICAL METHODS (2007)
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pavel Pugach et al.
VIROLOGY (2007)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
Distribution and three-dimensional structure of AIDS virus envelope spikes
Ping Zhu et al.
NATURE (2006)
Structural and molecular interactions of CCR5 inhibitors with CCR5
K Maeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
M Westby et al.
JOURNAL OF VIROLOGY (2006)
Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1
JM Strizki et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion
SR Mkrtchyan et al.
JOURNAL OF VIROLOGY (2005)
Generation and properties of a human immunodeficiency virus type I isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D)
AJ Marozsan et al.
VIROLOGY (2005)
Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry
AJ Marozsan et al.
JOURNAL OF VIROLOGY (2005)
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
C Watson et al.
MOLECULAR PHARMACOLOGY (2005)
Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization
JD Reeves et al.
JOURNAL OF VIROLOGY (2005)
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus
EJ Platt et al.
JOURNAL OF VIROLOGY (2005)
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20)
J Lu et al.
JOURNAL OF VIROLOGY (2004)
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor (vol 78, pg 2790, 2004)
SE Kuhmann et al.
JOURNAL OF VIROLOGY (2004)
HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion
M Cavrois et al.
VIROLOGY (2004)
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity
JD Reeves et al.
JOURNAL OF VIROLOGY (2004)
The CCR5 and CXCR4 coreceptors - Central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection
JP Moore et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2004)
Role of the human immunodeficiency virus type 1 envelope gene in viral fitness
HR Rangel et al.
JOURNAL OF VIROLOGY (2003)
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry
F Tsamis et al.
JOURNAL OF VIROLOGY (2003)
Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C
SC Ball et al.
JOURNAL OF VIROLOGY (2003)
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
JD Reeves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes
M Cavrois et al.
NATURE BIOTECHNOLOGY (2002)
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
A Trkola et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41
YN Xu et al.
FEBS LETTERS (2000)
Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion
GB Melikyan et al.
JOURNAL OF CELL BIOLOGY (2000)
Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1
SE Kuhmann et al.
JOURNAL OF VIROLOGY (2000)
Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus
PD Kwong et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
